Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAD+ and NMN in Refractory Primary Immune Thrombocytopenia
NCT06776510Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jan 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nicotinamide adenine dinucleotide, nicotinamide mononucleotide in immune thrombocytopenia (ITP), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Jan 2025; status: recruiting.
02
Drugs
nicotinamide adenine dinucleotidenicotinamide mononucleotide
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT06776510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06776510.